Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer

Zhao, Yongmei; Zheng, Yuxin; Zhu, Yan; Liu, Hongyun; Liu, Tianqing

doi:10.1186/s12951-022-01526-2

Cited by 50 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAMs, essential elements of the immune responses in TME, play a critical role in inhibiting tumor growth and metastasis ( 6 ). TAMs were divided into two phenotypes: tumor-suppressing M1 macrophages and tumor-promoting M2 macrophages.…”

Section: Exos As Drug Delivery Carrier For Cancer Immunotherapymentioning

confidence: 99%

“…In order to reactivate TME and enhance the efficiency of breast cancer therapy, Zhao et al. ( 6 ) designed and established exosome delivery system derived from M1 macrophage (DTX-M1-Exo). The results indicated that DTX-M1-Exo can promote the development of naïve macrophages into M1 phenotype.…”

Section: Exos As Drug Delivery Carrier For Cancer Immunotherapymentioning

confidence: 99%

“…These therapeutics often kill both cancer and normal cells, leading to severe side effects and drugs resistance ( 5 ). Therefore, it is critical to find an effective therapeutic approach with low or no side effects ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exosomes as smart drug delivery vehicles for cancer immunotherapy

et al. 2023

View full text Add to dashboard Cite

Exosomes (Exos) as drug delivery vehicles have been widely used for cancer immunotherapy owing to their good biocompatibility, low toxicity, and low immunogenicity. Some Exos-based cancer immunotherapy strategies such as tuning of immunosuppressive tumor microenvironment, immune checkpoint blockades, and cancer vaccines have also been investigated in recent years, which all showed excellent therapeutic effects for malignant tumor. Furthermore, some Exos-based drug delivery systems (DDSs) for cancer immunotherapy have also undergone clinic trails, indicating that Exos are a promising drug delivery carrier. In this review, in order to promote the development of Exos-based DDSs in cancer immunotherapy, the biogenesis and composition of Exos, and Exos as drug delivery vehicles for cancer immunotherapy are summarized. Meanwhile, their clinical translation and challenges are also discussed. We hope this review will provide a good guidance for Exos as drug delivery vehicles for cancer immunotherapy.

show abstract

Section: Exos As Drug Delivery Carrier For Cancer Immunotherapymentioning

confidence: 99%

Section: Exos As Drug Delivery Carrier For Cancer Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Exosomes as smart drug delivery vehicles for cancer immunotherapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Additionally, Zhao et al loaded a drug deferasirox with gemcitabine into a M1-macrophage-derived exosome to develop a co-delivery system, resulting in a significant anticancer effect on the GEM-resistant PANC-1/GEM cells and 3D tumor spheroids [ 89 ]. The exosomes derived from M1 macrophages are also reported as a carrier for the efficient delivery of other drugs [ 90 , 91 ].…”

Section: Exosome-induced Macrophage Polarization In Cancersmentioning

confidence: 99%

The Potential Use of Exosomes in Anti-Cancer Effect Induced by Polarized Macrophages

et al. 2023

View full text Add to dashboard Cite

The rapid development of aberrant cells outgrowing their normal bounds, which can subsequently infect other body parts and spread to other organs—a process known as metastasis—is one of the significant characteristics of cancer. The main reason why cancer patients die is because of widespread metastases. This abnormal cell proliferation varies in cancers of over a hundred types, and their response to treatment can vary substantially. Several anti-cancer drugs have been discovered to treat various tumors, yet they still have harmful side-effects. Finding novel, highly efficient targeted therapies based on modifications in the molecular biology of tumor cells is essential to reduce the indiscriminate destruction of healthy cells. Exosomes, an extracellular vesicle, are promising as a drug carrier for cancer therapy due to their good tolerance in the body. In addition, the tumor microenvironment is a potential target to regulate in cancer treatment. Therefore, macrophages are polarized toward M1 and M2 phenotypes, which are involved in cancer proliferation and are malignant. It is evident from recent studies that controlled macrophage polarization might contribute to cancer treatment, by the direct way of using miRNA. This review provides an insight into the potential use of exosomes to develop an ‘indirect’, more natural, and harmless cancer treatment through regulating macrophage polarization.

show abstract

“…They revealed that DTX-M1-Exo promoted polarization of naïve macrophages to M1 phenotype and maintained M1 form upon M2 stimulation through modulating mitochondrial function. Importantly, DTX-M1-sEVs has been demonstrated significantly improved the anti-cancer therapeutic efficacy with minimal side effect ( 183 ). Therefore, these trials showed encouraging results that sEVs may serve as early predictors for therapeutic response.…”

Section: Clinical Applications Of Sevs In Bcmentioning

confidence: 99%

The role and application of small extracellular vesicles in breast cancer

Huang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related deaths in women worldwide. Currently, patients’ survival remains a challenge in BC due to the lack of effective targeted therapies and the difficult condition of patients with higher aggressiveness, metastasis and drug resistance. Small extracellular vesicles (sEVs), which are nanoscale vesicles with lipid bilayer envelopes released by various cell types in physiological and pathological conditions, play an important role in biological information transfer between cells. There is growing evidence that BC cell-derived sEVs may contribute to the establishment of a favorable microenvironment that supports cancer cells proliferation, invasion and metastasis. Moreover, sEVs provide a versatile platform not only for the diagnosis but also as a delivery vehicle for drugs. This review provides an overview of current new developments regarding the involvement of sEVs in BC pathogenesis, including tumor proliferation, invasion, metastasis, immune evasion, and drug resistance. In addition, sEVs act as messenger carriers carrying a variety of biomolecules such as proteins, nucleic acids, lipids and metabolites, making them as potential liquid biopsy biomarkers for BC diagnosis and prognosis. We also described the clinical applications of BC derived sEVs associated MiRs in the diagnosis and treatment of BC along with ongoing clinical trials which will assist future scientific endeavors in a more organized direction.

show abstract

Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer

Cited by 50 publications

References 28 publications

Exosomes as smart drug delivery vehicles for cancer immunotherapy

Exosomes as smart drug delivery vehicles for cancer immunotherapy

The Potential Use of Exosomes in Anti-Cancer Effect Induced by Polarized Macrophages

The role and application of small extracellular vesicles in breast cancer

Contact Info

Product

Resources

About